Indications
Doxorubicin is primarily indicated for the treatment of various neoplastic conditions, including acute lymphoblastic leukemia and acute myeloblastic leukemia. It is also used in managing Hodgkin and non-Hodgkin lymphoma, as well as several metastatic cancers, such as breast, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, ovarian, transitional cell bladder, thyroid, gastric, and bronchogenic carcinoma. Furthermore, doxorubicin is utilized as a component of adjuvant therapy for women showing evidence of axillary lymph node involvement following the resection of primary breast cancer. The liposomal formulation is specifically indicated for ovarian cancer that has progressed or recurred post platinum-based chemotherapy, AIDS-related Kaposi's Sarcoma after unsuccessful prior systemic therapy or intolerance, and multiple myeloma in conjunction with bortezomib in patients previously untreated with bortezomib and those who have received at least one prior therapy.
Pharmacodynamics
Doxorubicin operates as a cytotoxic, cell-cycle non-specific anthracycline antibiotic. Its principal antitumor mechanism involves DNA structure destabilization through intercalation, leading to DNA strand breakages and subsequent damage. This action not only disrupts cellular transcriptomes but also can trigger apoptotic pathways if the DNA damage is irreparable. Additionally, doxorubicin's intercalative properties interfere with essential enzyme activities, including topoisomerase II, DNA polymerase, and RNA polymerase, resulting in cell cycle arrests. The generation of cytotoxic reactive oxygen species by doxorubicin further contributes to cellular damage.
Absorption
In patients with AIDS-related Kaposi's Sarcoma, administration of liposomal doxorubicin at 10 mg/m² yields a maximum concentration (Cmax) of 4.12 ± 0.215 μg/mL and an area under the curve (AUC) of 277 ± 32.9 μg/mL·h, indicating the drug's pharmacokinetic profile post-administration.
Metabolism
Doxorubicin undergoes three primary metabolic pathways: one-electron reduction, two-electron reduction, and deglycosidation, with approximately half of the administered dose excreted unchanged. The predominant metabolic route is two-electron reduction, where doxorubicin is converted to doxorubicinol by multiple enzymes, including several alcohol and carbonyl reductases. One-electron reduction, involving various oxidoreductases, leads to the formation of doxorubicin-semiquinone radicals. These radicals can be re-oxidized to doxorubicin, generating reactive oxygen species (ROS) and hydrogen peroxide, significantly contributing to adverse effects such as cardiotoxicity. Deglycosidation, a minor pathway, accounts for 1-2% of metabolism and involves reducing or hydrolyzing doxorubicin to deoxyaglycone or hydroxyaglycone forms, facilitated by enzymes like NADPH quinone dehydrogenase and xanthine oxidase.
Mechanism of Action
Doxorubicin exerts its antineoplastic effects primarily through two mechanisms: intercalation into DNA and the disruption of topoisomerase function, as well as the generation of free radicals leading to cellular damage. The drug intercalates into DNA via its anthraquinone ring, stabilizing the complex through hydrogen bonding with DNA bases. This intercalation introduces torsional stress in the polynucleotide structure, which destabilizes nucleosome arrangements, resulting in their eviction and replacement. Furthermore, the doxorubicin-DNA complex inhibits the activity of topoisomerase II by preventing the relegation of DNA breaks mediated by the enzyme, thereby obstructing replication and transcription processes and inducing apoptosis. Additionally, doxorubicin undergoes metabolism by microsomal NADPH-cytochrome P-450 reductase to form a semiquinone radical, which is reoxidized in the presence of oxygen, producing reactive oxygen species (ROS). These ROS are implicated in cellular damage through mechanisms such as lipid peroxidation, membrane disruption, DNA damage, oxidative stress, and the induction of apoptosis. While free radicals from this process can be neutralized by enzymes like catalase and superoxide dismutase, the deficiency of these enzymes in tumor and myocardial cells accounts for doxorubicin's efficacy against cancer cells and its associated cardiotoxicity.
